{{Rsnum
|rsid=11708067
|Gene=ADCY5
|Chromosome=3
|position=123346931
|Orientation=plus
|GMAF=0.1364
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ADCY5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 58.4 | 38.1 | 3.5
| HCB | 98.5 | 1.5 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 81.0 | 16.3 | 2.7
| ASW | 70.2 | 22.8 | 7.0
| CHB | 98.5 | 1.5 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 58.4 | 37.6 | 4.0
| LWK | 81.8 | 17.3 | 0.9
| MEX | 51.7 | 32.8 | 15.5
| MKK | 94.9 | 5.1 | 0.0
| TSI | 73.5 | 22.5 | 3.9
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=20081858
|Trait=Fasting glucose-related traits
|Title=New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
|RiskAllele=A
|Pval=3E-12
|OR=None
|ORtxt=None
|OA=1
}}

{{PMID Auto
|PMID=20490451
|Title=Type 2 diabetes risk alleles near ADCY5, CDKAL1 and HHEX-IDE are associated with reduced birthweight
}}

{{PharmGKB
|RSID=rs11708067
|Name_s=
|Gene_s=ADCY5
|Feature=
|Evidence=PubMed ID:20081858
|Annotation=Phenotype 1: In a meta-analysis of 21 GWAS cohorts followed by analysis in additional individuals, this SNP was found to be associated with fasting glucose level. Study size: 118,475. Significance metric(s): p = 7.1 x 10(-22). Phenotype 2: In the same study, this SNP was found to be associated with HOMA-B (homeostasis model assessment of beta-cell function). Study size: 94,212. Significance metric(s): p = 2.5 x 10(-12). Study population/ethnicity: Non-diabetic Individuals of European descent. Type of association: CO;GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165281938
}}

{{omim
|id=613460
|rsnum=11708067
}}

{{PMID Auto
|PMID=21887289
|Title=Glucose-Raising Genetic Variants in MADD and ADCY5 Impair Conversion of Proinsulin to Insulin
|OA=1
}}

{{PMID Auto
|PMID=21949744
|Title=Effects of 16 Genetic Variants on Fasting Glucose and Type 2 Diabetes in South Asians: ADCY5 and GLIS3 Variants May Predispose to Type 2 Diabetes
|OA=1
}}

{{PMID|20081857|OA=1
}} Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.

{{PMID Auto GWAS
|PMID=22693455
|Trait=None
|Title=Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases.
|RiskAllele=A
|Pval=6E-8
|OR=1.2500
|ORtxt=None
|OA=1
}}

{{PMID Auto GWAS
|PMID=22581228
|Trait=None
|Title=A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
|RiskAllele=
|Pval=3E-10
|OR=None
|ORtxt=None
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11708067
|overall_frequency_n=16
|overall_frequency_d=122
|overall_frequency=0.131148
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=10
}}

{{PMID Auto
|PMID=22698489
|Title=Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study.
}}

{{PMID Auto
|PMID=23462794
|Title=Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}